Home
Download
Press Centre
Latest News
Quarterly Newsletter
Clinical and Research Ethic Committee
Job Vacancies
2018 2018 | 2017 | 2016 | 2015 | 2014
Cervical Cancer Screening

High-risk HPV test combines with Pap smear (Co-testing) increases the ratio of cervical cancer or precancerous lesions detection

Cervical cancer is the 4th most common cancer in women worldwide. Cervical cancer is the 8th most common cancer and the 9th leading cause of cancer-related deaths amongst women in Hong Kong. Yet it is one of the truly preventable cancers.

The leading cause of cervical cancer is HPV (Human papillomavirus), which is responsible for more than 99 percent of all cases. Most HPV infections, precancerous lesions and early cervical cancer have no symptoms, and if treatment is not timely, the cancer will developto an advanced stage and is difficult to treat.  Therefore, regular screening (for example: Pap smear and high-risk HPV test) is very important for women.

An advanced screening method – Co-testing (High-risk HPV test + Pap smear)

  • High-risk HPV test
  • Pap smear

Pap smear is a traditional cervical cancer screening method, combining with high-risk HPV test (Co-testing) increased the ratio of cervical cancer or precancerous lesions detection from 57 – 74% to more than 90%*. Co-testing has been validated to be very effective in assessing the risk of cervical cancer and helping women to prevent cervical cancer.  The Hong Kong College of Obstetricians and Gynaecologists (HKCOG) has included co-testing in its latest 2016 Cervical Cancer Screening Guideline 12. Sample for both Pap smear and high-risk HPV test can be collected at the same time in a clinic before sending it to the laboratory for testing. Early risk identification allows physicians to take appropriate action to lower the risk of developing cervical cancer.

To raise the awareness of cervical cancer prevention, promotional discount is given on the Co-testing. For enquiries, please contact Obstetrics & Gynaecology Centre at
2339 7200.

Regular cervical cancer screening and timely treatment of the detected pre-cancerous changes can prevent cervical cancer.

 

For enquiries and appointments, please contact:

Obstetrics & Gynaecology Centre

Address

:

O&G Centre, LG1/F, Block D, Hong Kong Baptist Hospital

Telephone

:

2339 7200

Fax

:

2339 7204

Email

:

obgyn@hkbh.org.hk

 

--------------------------------------

*
1 Mayrand, MH, et al. Human Papillomavirus DNA versus Papanicolaou Screening Tests for Cervical Cancer. N Engl J Med 2007; 357:1579-1588
2 Coste J, et al. Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening.  BMJ. 2003;326(7392):733
3 Taylor, S, et al.  Direct comparison of liquid-based and conventional cytology in a South Africanscreening trial.  Int J Cancer. 2006;118(4):957-62
4 Ronco, G, et al. Human papillomavirus testing and Liquid-Based Cytology: Results at recruitment from the new technologies for Cervical Cancer randomized controlled trial. J Natl Cancer Inst. 2006;98:765-774
5 Sankaranarayanan, R, et. al, A critical assessment of screening methods for cervical neoplasia. Int J of Gynecology and Obstetrics (2005) 89, S4 — S12
Upload date: 16/10/17
網頁地圖 聯絡我們 免責聲明